Oncology and Hematology - Prova Education

Episodes 1-16 of 125

Collaborative Insights to Solve the Puzzle of Bladder Cancer
Collaborative Insights to Solve the Puzzle of Bladder Cancer
CME/CE
Collaborative Insights to Solve the Puzzle of Bladder Cancer
1.00 credit
- Daniel P. Petrylak, MD
- Elizabeth R. Plimack, MD, MS, FASCO
- Evan Y. Yu, MD
1.00 credit
Personalizing Care Within the RCC Treatment Paradigm
Personalizing Care Within the RCC Treatment Paradigm
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credit
- Eric Jonasch, MD
- Brad McGregor, MD
- Ulka Vaishampayan, MBBS
1.00 credit
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
MinuteCE®
Optimizing Ovarian Function Suppression in Hormone Receptor-Positive Breast Cancer: Best Practices for the Community Clinician
0.50 credits 4 episodes
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 credits 4 episodes
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
CME/CE
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
0.50 credits
- Javier Cortes, MD, PhD
- Hope S. Rugo, MD, FASCO
0.50 credits
Molecular Profiling for HER2+ Advanced Solid Tumors
Molecular Profiling for HER2+ Advanced Solid Tumors
CME/CE
Molecular Profiling for HER2+ Advanced Solid Tumors
1.00 credit
- Eric Van Cutsem, MD, PhD
- David SP Tan, MBBS, PhD, PRCP
- James Chih-Hsin Yang, MD, PhD
- Kathleen Moore, MD, MS, FASCO
1.00 credit
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
0.25 credits
- Jeffrey V. Matous, MD
- Donna Catamero, NP
0.25 credits
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CE
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
0.25 credits
- Jonathan Leventhal, MD
- Shahnaz Singh-Kandah, NP
0.25 credits
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits

Prev
1
2
3
…
7
8
Next

1/6